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Abstract
Background: The purpose of this study was to evaluate the clinical impact of oxaliplatin, leucovorin, and 5-
fluorouracil (FOLFOX-4) chemotherapy in terms of the response rate, progression-free/overall survival (PFS/OS) and
safety profile in patients with heavily pretreated recurrent epithelial ovarian cancer.
Methods: Clinical data were reviewed in 29 patients who received FOLFOX-4 as more than third-line chemotherapy,
consisting of 85mg/m2 of oxaliplatin, 200 mg/m2 of leucovorin, and bolus 400mg/m2 on day 1 of 5-fluorouracil,
followed by a 22-h infusion of 600mg/m2 of 5-fluorouracil for 2 consecutive days every 3 weeks. We also compared
the efficacy and toxicity of FOLFOX-4 with that of topotecan, a standard treatment, given at a dosage of 1.5 mg/m2
every three weeks in 26 patients.
Results: The median age of enrolled patients was 60 years (range 33 to 85). A median of 4 cycles (range 1–17) of
FOLFOX-4 were administered. Complete response and partial response were observed in one (3.5%) and 5 (17.2.2%)
patients, respectively, while stable disease was reported in 8 (27.6%) patients. Among all patients, grade 3–4 anemia,
neutropenia, and thrombocytopenia were observed in 0 (0%), 5 (17.2%), and 3 (10.3%) cases, respectively. Grade 3–4
fatigue was recorded in one (3.4%) patient and diarrhea in 2 (6.9%). Median PFS and OS were 2.8 months [95%
confidence interval (CI) 1.7–4.9] and 6.2 months (95% CI 2.4–14.6), respectively. No significant differences in terms of
efficacy and toxicity were observed between patients receiving FOLFOX-4 and those treated with topotecan.
Conclusions: The FOLFOX-4 regimen would seem to obtain similar survival rates to those of standard therapy with
topotecan in platinum-resistant ovarian cancer. Further randomized trials are warranted to confirm our findings.
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Background
Ovarian cancer remains a highly lethal malignancy, repre-
senting the sixth leading cause of cancer death in women
and the most lethal gynecologic malignancy [1, 2]. The
prognosis for advanced ovarian cancer has improved over
the last 10 years, especially thanks mainly to the
introduction of more personalized therapeutic strategies.
However, despite the high response rate to the standard
carboplatin-paclitaxel first-line combination, most patients
develop recurrent disease, with a median survival ranging
from 12 to 24months. Patients who progress on cisplatin
or carboplatin or who relapse within 6months of the end
of treatment show the poorest outcome [2]. Single-agent
therapies for platinum-refractory/resistant patients include
oral etoposide, taxanes, topotecan, gemcitabine, vinorelbine,
liposomal doxorubicin, and oxaliplatin, with response rates
of around 15–20% and an overall survival (OS) of less than
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12months [3]. Research is now aiming to improve chemo-
therapy, identify novel, effective and well-tolerated agents,
and overcome platinum resistance.
Cisplatin and carboplatin are the most common platinum
compounds used to treat ovarian cancer. Oxaliplatin, a dia-
minocyclohexane platinum compound, has a different
spectrum of activity and toxicity to that of other platinum
agents and does not usually show cross-resistance with cis-
platin and carboplatin in ovarian cancer [4, 5]. In previous
phase II studies, oxaliplatin at a dose of 130mg/m2 every 3
weeks was administered to patients with cisplatin- or
carboplatin-refractory/resistant and taxane-pretreated ovar-
ian cancer, obtaining response rates of 4.3–29.0% and a me-
dian OS of 9.5–15months [6–9]. The combination of
5-fluorouracil with leucovorin given as intravenous bolus or
continuous infusion has also been used to treat
platinum-resistant/recurrent ovarian cancer but has shown
limited clinical activity [10–14].
Some in vitro studies indicate a potential synergy be-
tween oxaliplatin and 5-fluorouracil/leucovorin [15]. The
combination of these drugs (called FOLFOX) represents
a standard chemotherapeutic regimen in the manage-
ment of some advanced tumours [16–18]. Preliminary
data on the use of this treatment in recurrent ovarian
cancer have not been entirely satisfactory/have not been
encouraging [19–22]. In the present study we evaluated
the efficacy, in terms of clinical outcome, and toxicity of
FOLFOX-4 in platinum-resistant ovarian cancer. In
addition, through an exploratory analysis, we compared
our results with data from patients treated with topote-
can, a drug usually administered alone as salvage chemo-
therapy in platinum-resistant disease.
Methods
Study population
We retrospectively evaluated 29 patients treated with
the FOLFOX-4 regimen from February 2008 to April
2016 as the primary cohort, and 26 patients treated with
topotecan between August 2010 and December 2014 as
the secondary cohort. Eligibility criteria of both cohorts
were histological confirmation of epithelial ovarian can-
cer, previous treatment with cisplatin or carboplatin plus
paclitaxel regimens, and disease recurrence during treat-
ment with or within 6 months of the end of the cisplatin
or carboplatin-based chemotherapy. Additional eligibility
criteria included Eastern Cooperative Oncology Group
(ECOG) performance status 0–2, and adequate cardiac,
renal, hepatic and bone marrow function. Metastatic dis-
ease was documented by bone scan, computed tomog-
raphy or magnetic resonance imaging. The retrospective
study was approved by the Institutional Review Board of
Istituto Scientifico Romagnolo per lo Studio e la Cura
dei Tumori (IRST) IRCCS and was conducted in accord-
ance with the ethical standards laid down in the 1964
Declaration of Helsinki. The need for written informed
consent from participants was waived because of the
retrospective nature of the research.
Patients were evaluated for safety and dosing compliance
every 2 weeks for the first 3months of chemotherapy, and
then monthly thereafter until treatment discontinuation.
Renal, liver and bone marrow function were assessed at
every cycle, while cancer antigen 125 (CA-125) and radio-
graphic evaluation were left to the discretion of the treating
physician, but were usually performed after at least three
months’ treatment.
Treatment and evaluation
Treatment with FOLFOX-4 consisted of 85 mg/m2 of
oxaliplatin as a 2-h infusion on day 1, 200 mg/m2 of leu-
covorin as a 2-h infusion on day 1, and bolus 400 mg/m2
of 5-fluorouracil on day 1, followed by a 22-h infusion of
600 mg/m2 of 5-fluorouracil for two consecutive days
every three weeks. Topotecan was administered at a dos-
age of 1.5 mg/m2 by intravenous infusion daily for 5 con-
secutive days, starting on day 1 of a 21-day course. Both
therapeutic regimens were administered continuously
until there was evidence of either progressive disease (PD)
or unacceptable toxicity. Prophylactic granulocyte-colony
stimulating factor was only permitted for patients who de-
veloped grade 3–4 neutropenia or febrile neutropenia.
Tumor response was evaluated every three cycles by
repeating baseline assessments using imaging studies
(computed tomography and/or magnetic resonance im-
aging) according to the Response Evaluation Criteria in
Solid Tumors (RECIST) for patients with measurable dis-
ease [23]. CA-125 was evaluated in recurrent disease using
CA-125 response criteria developed by the Gynecologic
Cancer InterGroup [24]. Toxicity was graded using the
National Cancer Institute Common Terminology Criteria
for Adverse Events (CTCAE), version 4 [25].
Statistical analysis
All data were analyzed by descriptive statistics. Relation-
ships between patient characteristics were testing using
the Chi-square test for categorical variables and the me-
dian test for continuous variables. The Kaplan-Meier
method was used to estimate PFS and OS, with two-sided
95% confidence intervals (95%CI). PFS was defined as the
time from the start of FOLFOX-4 or topotecan until dis-
ease progression or last tumor evaluation or death from
any cause. OS was defined as the time from the start of
FOLFOX-4 or topotecan until death from any cause or
last follow-up. Survival curves were compared using the
log-rank test. Due to exploratory intent, no multiple test-
ing correction was performed. All statistical analyses were
carried out with SAS statistical software, version 9.4 (SAS
Institute, Cary, NC, USA). A two-sided P-value < 0.05 was
deemed statistically significant for all the analyses.
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Results
Patient characteristics
The median age was significantly different in the FOLFOX-4
and topotecan populations (60 years [range 33–85] and 66
years [range 51–80]), respectively (P= 0.032). FOLFOX-4-
treated patients showed a higher incidence of abdominal and
extra-abdominal metastases (18 [62.1%] vs. 6 [23.1%])
(P= 0.004). All patients had previously received a median of
4 (range 1–17) and 3 (range 1–8) cycles of FOLFOX-4 and
topotecan, respectively (P = 0.038). Fourteen (48.3%) and 6
(23.1%) patients had received more than 4 treatments before
FOLFOX-4 and topotecan, respectively (P= 0.055), whose 2
(range, 1–4) including a platinum-based treatment in both
FOLFOX-4 and topotecan groups. Among FOLFOX-4 pa-
tients receiving a prior platinum-based treatment, we re-
ported a recurrent and refractory disease in 19 (65.5%) and
10 (34.5%) patients, respectively, whilst we observed a recur-
rent and refractory cancer in 17 (64.4%) and 9 (35.6%),
respectively, in the topotecan-treated patients. In the
FOLFOX-4 group, a prior treatment with topotecan was re-
ported in 4 (13.8%) patients, and only one (3.8%) patient re-
ceived a prior therapy with FOLFOX-4 in the topotecan
group. Among pre-treatment laboratory parameters, the in-
cidence of neutrophil-to-lymphocyte ratio (NLR) ≥ 3 was
significantly higher in patients treated with FOLFOX-4
than in those receiving topotecan (15 [53.6%] vs. 7
[28.0%]) (P = 0.013). Patient characteristics are summa-
rized in Table 1.
Treatment outcomes
All patients treated with FOLFOX-4 and topotecan
chemotherapy had measurable disease and were evalu-
able for tumor response by RECIST criteria (Table 2). Of
the 29 patients treated with FOLFOX-4, 1 (3.5%) showed
a complete response (CR), 5 (17.2%) a partial response
(PR) and 8 (27.6%) stable disease (SD). Of the 26 topote-
can patients, 1 (3.8%) had a CR, 1 (3.8%) a PR and 6
(23.1%) SD. Objective response was assessed by Rustin
et al.’s [25] CA-125 criteria using the baseline CA-125
value as reference. Five patients treated with FOLFOX-4
and 8 with topotecan were not evaluable by Rustin’s
CA-125 criteria. A CA-125 response was observed in 11
(44.0%) FOLFOX-4 patients and 5 (26.3%) topotecan pa-
tients (Table 2). The decrease in CA-125 levels was consist-
ent with and not influenced by ascitic drainage. However, an
objective radiological response (CR or PR) was not associ-
ated with CA-125 response. Median follow-up was 45
months (range 1–45) for patients treated with FOLFOX-4
and 57months (range 1–57) for those receiving topotecan.
The FOLFOX-4 group showed a median PFS and OS of 2.8
months (range 1.7–4.9) and 6.2months (range 2.4–14.6),
respectively. Topotecan patients had a median PFS and OS
of 2.8 months (range 1.8–4.9) and 10.4 months (range
4.9–19.5), respectively (Table 2). A comparison of
survival curves between the 2 treatment groups did not re-
veal a significant difference in PFS (Fig. 1) and OS (Fig. 2).
Univariate analysis did not identify any significant fac-
tors (including site of metastasis, previous treatment lines,
baseline NLR and platelet-to-lymphocyte ratio [PLR]) that
predicted PFS (Table 3) and OS (Table 4) within each
treatment group and between patients treated with
FOLFOX-4 and topotecan, with the exception of NLR, a
significant predictor of OS in FOLFOX-4 (P = 0.013).
At the time of analysis, 1 (3.4%) patient in the FOLFOX-4
group and 2 (7.7%) in the topotecan group were still alive.
After progression on FOLFOX-4 or topotecan, 16 (57.1%)
and 17 (65.4%) patients, respectively, underwent new treat-
ments (Table 2).
Safety and tolerability
The incidence of grade 3–4 toxicity, in particular myelo-
toxicity, was similar in patients treated with FOLFOX-4
and topotecan (Table 5). Ten (34.5%) and 2 (7.7%) pa-
tients reduced FOLFOX-4 and topotecan dosage due to
chemotherapy-related adverse events, respectively. How-
ever, only 2 (6.9%) undergoing FOLFOX-4 and 3 (11.5%)
receiving topotecan discontinued treatment because of
unacceptable toxicity.
Discussion
Despite relatively high response rates to first-line
platinum-based therapies for epithelial ovarian cancer,
the majority of patients relapse and a number of
treatment-related deaths have also been reported.
New-generation chemotherapeutic drugs and biological
agents, especially those targeting angiogenesis [26] and the
nuclear enzyme poly-(ADP-ribose) polymerase (PARP) [27,
28], have recently been introduced into clinical practice, in-
creasing the number of therapies available for relapsed or
refractory disease. Consequently, patients with advanced
ovarian cancer often undergo multiple chemotherapy
courses in an effort to achieve long-term remission and
maintain an acceptable quality of life. The main risk from
using an increasing number of therapeutic agents is cumu-
lative toxicity, especially myelotoxicity, which may influence
subsequent treatments. Hence the need for new, effective
and less toxic therapies in patients with recurrent and per-
sistent disease after failure of chemotherapy.
In the present retrospective monoinstitutional study, we
analyzed the results obtained in a population of ovarian
cancer patients treated with FOLFOX-4 or standard topo-
tecan monotherapy in terms of clinical impact on out-
come and toxicity. The choice of therapy and dosing
schedule was at the discretion of the treating physician, as
was the possibility of initial dose reduction due to older
age and poor performance status. Efficacy and safety were
comparable in both regimens, with hematological toxicity
the most frequent reason for dose reduction. Treatment
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Table 1 Patient Characteristics
FOLFOX-4 (n = 29) Topotecan (n = 26) P
N (%) N (%)
Median age, years (range) 60 (33–85) 66 (51–80) 0.032
Histology
Serous 22 (75.9) 22 (84.6)
Non-serous 7 (24.1) 4 (15.4) 0.422
FIGO stage at presentation
I-II 3 (14.3) 2 (12.5)
III 16 (76.2) 11 (68.7)
IV 2 (9.5) 3 (18.8) 0.529
Unknown/missing 8 10
Grade
I 5 (20.8) 7 (29.2)
II 5 (20.8) 4 (16.7)
III 14 (58.4) 13 (54.1) 0.612
Unknown/missing 5 2
ECOG Perfomance status
0–1 27 (93.1) 25 (96.1)
2 2 (6.9) 1 (3.9) 0.622
Sites of metastasis
Only abdominal 11 (37.9) 20 (76.9)
Abdominal + extra-abdominal 18 (62.1) 6 (23.1) 0.004
Number of involved sites
1 4 (13.8) 5 (19.2)
2 10 (34.5) 10 (38.5)
≥ 3 15 (51.7) 11 (42.3) 0.459
Median interval from initial diagnosis, months (range) 47 (11.5–248) 40.4 (9.7–1301) 0.129
Lines of previous treatments
≤ 4 15 (51.7) 20 (76.9)
> 4 14 (48.3) 6 (23.1) 0.055
Number of treatment cycles
Median value (range) 4 (1–17) 3 (1–8) 0.038
Baseline NLR
< 3 13 (46.4) 20 (80.0)
≥ 3 15 (53.6) 5 (20.0) 0.013
Unknown/missing 1 1
Baseline PLR
< 210 13 (46.4) 18 (72.0)
≥ 210 15 (53.6) 7 (28.0) 0.062
Unknown/missing 1 1
Median baseline Hb, g/dL (range) 11.1 (8.3–15.0) 12.1 (8.9–14.3) 0.058
Median baseline Ca125, ng/mL (range) 289.9 (13.3–11,344.0) 100.2 (12.6–10,805.0) 0.259
Median baseline BMI, kg/m2 (range) 23.88 (15.24–32.04) 23.16 (19.53–30.30) 0.345
Abbreviation. BMI body mass index, ECOG Eastern Cooperative Oncology Group, FIGO International Federation of Gynecology and Obstetrics, FOLFOX-4 oxaliplatin,
leucovorin, and 5-fluorouracil, Hb hemoglobin, NL ,neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
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discontinuation due to toxicity was rare. Despite dose limit-
ing cumulative neurotoxicity of oxaliplatin-based therapy,
only one case presented a grade 4 neurotoxicity, although
grade 2 neurotoxicities had a negative impact on the quality
of life in a few cases heavily pretreated with taxane- and
platinum-based therapies.
In terms of response, our findings were comparable to
those of other studies [19–22] on patients with measurable
disease. Major limitations of this study were a small number
of patients, the retrospective design, and the presence of
mismatch of the cohorts related to a lack of randomization.
We observed that NLR was the only prognostic factor in
our patient cohort, as reported in a recent meta-analysis
[29]. However, due to exploratory intent, no multiple testing
correction was performed. Although adjustments for mul-
tiple comparisons can help control the study-wide false-
positive rate, for exploratory analyses it is more important to
judge P values cautiously than to try to formally determine
their true significance level. Precise adjustment of P values
and confidence intervals is often impractical in the context
of exploratory research but can be useful for
hypothesis-driven research.
Despite all these several limitations of this study, we
showed similar treatment outcomes (PFS, OS, and CA-125
Table 2 Treatment outcome
FOLFOX-4 (n = 29) Topotecan (n = 26)
Median follow-up, months (range) 45 (1–45) 57 (1–57)
Median PFS, months (95% CI) 2.8 (1.7–4.9) 2.8 (1.8–4.9)
Median OS, months (95% CI) 6.2 (2.4–14.6) 10.4 (4.9–19.5)
Tumor response, n (%)
CR 1 (3.5) 1 (3.8)
PR 5 (17.2) 1 (3.8)
SD 8 (27.6) 6 (23.1)
PD 15 (51.7) 18 (69.3)
Ca125 response*, n (%) 11 (44.0) 5 (26.3)
Number of patients receiving new treatment after progression, n (%) 16 (57.1) 17 (65.4)
*According to Rustin’s criteria
Abbreviations. CR complete response, FOLFOX-4 oxaliplatin, leucovorin, and 5-fluorouracil, n number, PFS progression-free survival, PD progressive disease, PR
partial response, OS overall survival, SD stable disease
Fig. 1 Progression-free survival (PFS) from start of FOLFOX-4 and topotecan treatments
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Fig. 2 Overall survival (OS) from start of FOLFOX-4 and topotecan treatments
Table 3 Univariate subgroups analysis of progression-free survival
FOLFOX-4 TOPOTECAN
No. patients No. events Median PFS (95% CI) No. patients No. events Median PFS (95% CI) P
Site of metastasis
Only abdominal 11 10 2.8 (0.6–5.6) 20 20 2.7 (1.1–3.6) 0.617
Abdominal+extra-abdominal 18 18 2.8 (1.7–7.0) 6 6 5.0 (0.9–10.7) 0.941
P 0.544 0.211
Lines of previous treatments
≤ 4 15 15 2.6 (0.6–4.6) 20 20 3.2 (1.6–5.4) 0.948
> 4 14 13 2.8 (1.7–8.4) 6 6 2.2 (0.7–4.9) 0.124
P 0.401 0.054
Baseline NLR
< 3 13 12 3.0 (2.4–18.5) 20 20 2.9 (1.6–5.1) 0.142
≥ 3 15 15 1.9 (0.7–4.6) 5 5 2.5 (1.0–6.6) 0.690
P 0.075 0.388
Baseline PLR
< 210 13 12 2.9 (0.7–18.5) 18 18 2.9 (1.6–5.1) 0.235
≥ 210 15 15 2.5 (0.9–4.6) 7 7 2.5 (0.9–3.5) 0.539
P 0.177 0.154
Abbreviation. FOLFOX-4 oxaliplatin, leucovorin, and 5-fluorouracil, CI confidence interval, NLR neutrophil-to-lymphocyte ratio, PFS progression-free survival, PLR
platelet-to-lymphocyte ratio
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response) between FOLFOX-4 and topotecan group. Spe-
cifically, there were fewer cases of PD (15 [51.7%] vs.18
[69.3%]) and a similar number of SD (8 [27.6%] vs. 6
[23.1%]) in FOLFOX-4 compared to topotecan patients.
FOLFOX-4 could thus represent a potential alternative to
standard chemotherapy, with a similar toxicity profile, in
this patient setting. However, more recent studies [30] sug-
gested different dose regimes of topotecan characterized by
reduced number of side effects and thus this could alter the
comparison of toxicities between FOLFOX-4 and topotecan
profiles in our study.
The present study did not bring to light any clinical prog-
nostic factors for PFS and OS in either treatment group,
probably because of the small sample size and the lack of
adequate patient selection. In addition, currently, there are
no biomarkers able to improve the selection of patients
candidates to FOLFOX-4 combination. Potential predictive
biomarkers could derive from the analysis of homologous
recombination deficiencies such as BRCA1/2 alterations,
especially because they are of particular interest for
platinum-based regimens. Therefore, future clinical trials in
this disease setting could be supported by genomic and
proteomic studies to identify prognostic factors associated
with response to fluorouracil. The advances made in gen-
etic and molecular biology could provide a valuable insight
into the alterations underlying these types of ovarian cancer,
and the relationship between the mechanism of action of
fluorouracil and the subsequent downstream molecular
pathways activated during tumorigenesis and disease
progression.
Table 4 Univariate subgroups analysis of overall survival
FOLFOX-4 TOPOTECAN
No. patients No. events Median PFS (95% CI) No. patients No. events Median PFS (95% CI) P
Site of metastasis
Only abdominal 11 11 5.0 (1.3–14.6) 20 18 10.4 (2.9–25.0) 0.166
Abdominal+extra-abdominal 18 17 8.2 (2.4–16.7) 6 6 12.7 (2.7–23.4) 0.919
P 0.771 0.492
Lines of previous treatments
≤ 4 15 15 10.2 (1.3–16.7) 20 18 10.5 (2.7–25.0) 0.057
> 4 14 13 5.5 (2.4–14.6) 6 6 10.4 (2.9–16.2) 0.789
P 0.753 0.206
Baseline NLR
< 3 13 12 14.6 (3.8–22.9) 20 18 10.4 (4.9–23.4) 0.870
≥ 3 15 15 5.4 (1.2–10.2) 5 5 2.9 (1.5–15.0) 0.858
P 0.013 0.051
Baseline PLR
< 210 13 12 13.0 (1.8–18.9) 18 16 10.5 (4.9–23.3) 0.514
≥ 210 15 15 5.6 (1.3–14.1) 7 7 10.0 (1.5–15.0) 0.660
P 0.275 0.061
Abbreviations. FOLFOX-4 oxaliplatin, leucovorin, and 5-fluorouracil; number; CI confidence interval, NLR neutrophils-to-lymphocyte ratio, OS overall survival, PLR
platelet-to-lymphocyte ratio
Table 5 Toxicity in FOLFOX-4 and Topotecan cohorts
FOLFOX-4 (n = 29) Topotecan (n = 26)
Grade 3 n(%) Grade 4 n(%) Grade 3 n (%) Grade 4 n(%)
Anemia – – 2 (7.7) 1 (3.8)
Neutropenia 3 (10.3) 2 (6.9) – –
Thrombocytopenia 1 (3.4) 2 (6.9) 2 (7.7) 1 (3.8)
Fatigue 1 (3.4) – 1 (3.8) –
Neurotoxicity – 1 (3.4) – –
Hepatotoxicity – – 1 (3.8) –
Diarrhea 2 (6.9) – – –
Abbreviations. FOLFOX-4 oxaliplatin, leucovorin, and 5-fluorouracil, N number
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Conclusion
The retrospective nature of our study and the small sam-
ple size do not allow for definitive conclusions to be
drawn. However, our results provide further evidence that
the FOLFOX-4 regimen may be as effective as standard
monotherapies and could be proposed as an appropriate
salvage treatment in refractory or resistant ovarian cancer.
However, it should be appropriate to consider these
heavily-pretreated patients as an ideal group for clinical
trials; particularly given the success or emerging data of
some newer classes of targeted therapies such as PARP in-
hibitors, antivascular drugs, dual antibody like molecules,
antibody drug conjugates and so randomized multicenter
trials comparing the FOLFOX-4 regimen, alone or, par-
ticularly, in combination with targeted therapy, are war-
ranted to improve the standard of care in patients with
heavily-pretreated disease.
Abbreviations
95%CI: 95% confidence interval; CA-125: cancer antigen 125; CR: complete
response; CTCAE: Common Terminology Criteria for Adverse Events;
ECOG: Eastern Cooperative Oncology Group; FOLFOX-4: oxaliplatin plus
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